ReviewIJID regions2026
Melioidosis in India: A systematic review of individual cases.
Review in IJID regions, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Computed Tomographic Features Associated with Pulmonary Melioidosis versus Pulmonary Tuberculosis in Diabetic Patients: A Retrospective Comparative Cohort Study.The American journal of tropical medicine and hygiene · 2026Article
- Melioidosis Presenting as a Solitary Liver Abscess With Culture-Negative Septic Arthritis: A Case Report.Cureus · 2026Article
- Reconsidering throat swab culture in melioidosis: diagnostic stewardship with clinical nuance.Journal of clinical microbiology · 2026Article
- Clinicopathological Spectrum of Brain Parenchymal Infections: A Retrospective Analytical Study.Cureus · 2026Article
- Tibial Osteomyelitis due to Burkholderia pseudomallei in a Non-diabetic Patient: A Case Report.Journal of orthopaedic case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Melioidosis is increasingly recognized in India, but available evidence remains fragmented across small reports. We aimed to synthesize national case-based data to describe the clinical spectrum and identify factors associated with mortality. Methods: We systematically searched PubMed, Embase, and Web of Science from inception to February 5, 2025. Case reports, case series, and observational cohorts with individual patient-level culture- or molecular-confirmed data from India were included. Two reviewers independently screened studies, extracted data using a standardized form, and assessed quality using the Joanna Briggs Institute checklist for case reports. Univariate comparisons were performed between survivors and non-survivors. The protocol was registered on PROSPERO (CRD42025640317), and PRISMA guidelines were followed. Results: From 1983 screened records, 209 studies reporting 558 cases from 20 states were included. The mean age was 44.8 years, and 73.4% had diabetes. Bacteremia occurred in 70.1%; pulmonary disease (33.2%), bone/joint involvement (35.1%), splenic abscesses (17.7%), and central nervous system disease (13.3%) were the most common conditions. Among 498 cases with reported outcomes, mortality was 19.9%. Malignancy, pulmonary and central nervous system involvement, and bacteremia were associated with death. Conclusions: In India, melioidosis is widespread and often severe, with substantial mortality. Earlier recognition and improved diagnostic access are needed to reduce preventable deaths.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.